Posted on

Psyence Group Functional Mushroom Brand “GOODMIND” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

Psyence Group Functional Mushroom Brand “GOODMINDTM” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

Toronto, Canada/ December 2, 2021 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

The product is available for sale in a sachet format, which can be added to any beverage, or it can be ordered as a GOODMINDTM Functional Mushroom Cappuccino. GOODMINDTM is jointly owned by Psyence and South African natural wellness company Goodleaf.

“Following the launch of our first Functional Mushroom product, GOODMINDTM (in capsule format) in August 2021, we recognised the opportunity to extend the GOODMINDTM offering. We have now developed GOODMINDTM water-soluble, mushroom powder sachets, which blends perfectly with coffee and other beverages,” says Jody Aufrichtig, Executive Chairman Psyence Group.” We are proud of the GOODMINDTM products we have developed and that we are able to generate revenue from having our wellness products on shelves.”

Goodmind Vida E Caffe

Goodleaf CEO and Founder Warren Schewitz says: “Collaborating with vida e caffè to launch South Africa’s first Functional Mushroom Cappuccino made perfect sense. vida e caffè has a network of over 250 coffee stores nationwide and the Functional Mushroom Cappuccino will be available in a selection of these stores. The brand is synonymous with innovation and is experienced in bringing new products to market.”

Darren Levy CEO, vida e caffè says:  “We are constantly on a journey to see how we can enhance our coffee and health offering to the end consumer, and are committed to staying on trend with global coffee developments. Following previous collaborations in the CBD space and recent collagen additions to our menu, we have seen that our consumers enjoy having functional benefits added to their daily brew. We are excited to be collaborating with the GOODMIND team on this new and innovative coffee add-on offering, promoting a healthy body and mind.”

The global Functional Mushroom market was valued at USD 25.4 billion in 2020, and is projected to reach a CAGR of 8.44% during the forecast period 2021-2026. This is according to a Functional Mushrooms Market 2021 report published by Research and Markets in October 2021. The report highlights that while demand for mushroom-based products had been increasing for some time, functional mushrooms have been ‘brought into the spotlight’ as a result of Covid-19 and the category is experiencing accelerated growth.

The GOODMIND™ Functional Mushroom range has been developed using a blend of adaptogenic, non-psychedelic super mushrooms. The GOODMIND™ mushroom powder sachets are a blend of eight functional mushrooms, predominantly Lion’s Mane, Shiitake, Cordyceps and Chaga.

ABOUT PSYENCE GROUP: www.psyence.com

Psyence is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.

Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.

Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development.  We work to develop advanced natural psilocybin products for clinical research and development.  We have entered into a long term joint venture to launch mushroom-based mental wellness focused nutraceutical products, the GOODMIND™ collection, to support improved focus, calm, and sleep.

Our key divisions, Psyence Production, Psyence Therapeutics, and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Jamaica, South Africa and a presence in the United States and Australia.

For more info on the GOODMIND™ website: https://foragoodmind.com/

About vida e caffè

 vida e caffè is a privately-owned coffee shop franchise and supplier of beverage products in South Africa. The name vida e caffè mixes Spanish or Portuguese for ‘life’ with Italian for ‘and coffee’. The coffee chain has over 250 stores throughout South Africa and 22 on the rest of the African continent.

Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively “the Company“) are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding consumer uptake of GOODMINDTM products and functional mushroom products in general in South Africa, product requirements, consumer demands and product market fit in South Africa, revenue generation from the GOODMINDTM products, the size and growth of the global Functional Mushroom market, the effect of the COVID-19 epidemic, and market conditions and economic factors effecting the GOODMINDTM business and roll-out and the functional mushroom market in general. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Posted on

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus’ Research and Development capabilities and generate revenue through third-party clients

VANCOUVER, BC, Nov. 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing, which was developed and validated in-house, will be available as part of its service offerings for third-party clients and used for evidence-based conversations with the regulators.

As a global leader in psychedelics testing Numinus Bioscience continues to make strides in the development of analytical testing methods for the psychedelics industry. Amongst the matrices for which methodologies are being developed are Psilocybe mushroom fruiting bodies, extracts, and derivatives and, coupled with required testing such as contaminants and residues, the lab has validated methods for active constituents.  The Psilocybe mushrooms constituent screen includes Psilocybin, Psilocin, Baeocystin, Norbaeocystin and Tryptophan, Norpsilocin and Aeruginascin which represent the most well-defined alkaloids for Psilocybe species.

“The testing we’ve developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry,” says Sharan Sidhu, Science Officer and General Manager. “Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products.”

In addition to screening for therapeutically active constituents, the lab has successfully developed a psychedelic mushroom toxicity screen that includes nephrotoxic and hepatotoxic compounds. Although the platform has been developed for industry, the screen can quickly identify toxins from several varied species and is being offered to healthcare providers to identify toxins in poison control responses, demonstrating the value of this research beyond the psychedelic industry. Toxicity scans are completed using the Orbitrap, a state-of-the-art, industry leading high resolution mass spectrometry instrument.

“These in-house validated methods are another example of success in analytical development at Numimus, showing our commitment to strengthen regulatory confidence in these products,” says Payton Nyquvest, CEO and Founder, Numinus. “We continue to push the boundaries as we establish our role as The Center of Excellence for Psychedelic Research and Development, with the furtherment of the industry at the heart of our advancements.”

The research team has thus far characterized over 260 compounds, many of them characterized for the first time in psychedelic mushrooms and continues to make novel discoveries in research and development of Psilocybin. Numinus Bioscience also continues to build testing capabilities for Ketamine, LSD, Mescaline, DMT and MDMA.

About Numinus
Numinus Wellness (TSXV: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, , “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Numinus Wellness Inc.

For further information: May Lee, Communications Manager, Numinus, may.lee@numinus.com; For investor inquiries: Jamie Kokoska, VP, Investor Relations, Numinus, jamie.kokoska@numinus.com

Related Links

https://numinus.ca/

Posted on

GIVEAWAY ALERT 🚨

Join the CPA Community & Win!

You could win $4,000+ in prizes for supporting legal access to psychedelics!

By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.

If that’s not enough, you’ll also be entered to win an incredible prize package including:

  • A scholarship towards a Holos Plant Medicine retreat (Value: $1,500)
  • A 2-night stay at the Sentinel Retreat Centre (Value: $500)
  • A functional mushroom wellness package from Eversio Wellness (Value: $300)
  • 1 of 3 Physiology of Trauma premium masterclass packages from Nectara (Value: $900)
  • And more!

Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.

Purchase a membership before December 10th to be entered in the giveaway!

Posted on

Win + Support + Microdose + Covid-19 🍄: issue 25

Here’s what’s in store for you in today’s issue:

🍄 Results from a global microdosing study

🍄  Ayahuasca vs. placebo

🍄 3D-printed psychedelics

🍄 Can mushrooms fight covid?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Where Religion And Psychedelics Collide

In this episode of the Daily Mushroom Podcast, we have Peg Peters. Peg is setting up a ketamine-assisted psychotherapy clinic just outside of Vancouver, BC. He discovered psychedelics in his mid 40s, taking a 6g dose of psilocybin mushrooms while accompanied by a therapist. After that experience his career in psychedelics took off!

Therapeutic banner

Ayahuasca vs placebo

An ayahuasca retreat could make you more empathetic!

In a recent study, participants reported reduced stress, anxiety, and depression after attending an ayahuasca ceremony… even those who were given a placebo. 

However, only the ayahuasca users showed increased empathy.

The supportive group atmosphere could explain why people experienced benefits even without taking ayahuasca. 

Don’t get triggered

Researchers discovered that DOI (a psychedelic that’s similar to LSD and mescaline) can reduce anxiety and increase neural plasticity. Rats stopped showing anxious behaviours in response to fear triggers after a single dose!

How psychedelic ceremonies change your beliefs

A survey of ~900 psychedelic ceremony attendees revealed that psychedelic use is associated with a decreased belief in materialism, an increase in transcendentalism, and improved mental health. Participants showed more moderate views on metaphysical beliefs after the ceremony rather than extreme stances.

inspirational banner

GIVEAWAY ALERT 🚨

You could win $4,000+ in prizes for supporting legal access to psychedelics!

By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.

If that’s not enough, you’ll also be entered to win an incredible prize package including:

  • A scholarship towards a Holos Plant Medicine retreat (Value: $1,500)
  • A 2-night stay at the Sentinel Retreat Centre (Value: $500)
  • A functional mushroom wellness package from Eversio Wellness (Value: $300)
  • 1 of 3 Physiology of Trauma premium masterclass packages from Nectara (Value: $900)
  • And more!

Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.

Purchase a membership before December 10th to be entered in the giveaway!

Get ready for a psychedelic TV series coming this summer!

This month’s issue of Los Angeles Magazine features an in-depth cover story on the city’s recent obsession with psychedelics. 

Now, the story is being developed into a drama/comedy series called Psychedelic City (think Silicon Valley meets Limitless).

The writer hopes the show will “wipe away some of the stigmas that have been attached to psychedelics.”

The developers are also creating a Psychedelic City metaverse platform with immersive art, music, and experimental therapies. 

business banner

Biomind Labs (BMND) developed a new way to manufacture psychedelics using 3D printers and lasers. By printing the formulation layer by layer, the company can control exactly when the drug is released and adjust doses for each patient.

LOVE Pharma (LUV) signed a letter of intent to acquire Microdoz Therapy Inc. to accelerate a psilocybin trial for cannabis use disorder. Seems ironic considering that the company also sells THC and CBD oral strips!

Entheon Biomedical (ENBI) has begun testing the stability of its DMT formulation in preparation for a study on nicotine addiction.

PharmaTher (PHRM) applied for an orphan drug designation for a ketamine treatment for a rare seizure condition called Status Epilepticus. If approved, the designation would give the company potential tax credits, grant eligibility, and exclusive marketing rights.

Pasithea Therapeutics (KTTA) began offering an esketamine nasal spray at its UK clinics. It’s one of just three clinics in the UK that have been approved to provide the treatment.

MYND Life Sciences (MYND) began research on its biomarker test that aids in diagnosing multiple sclerosis. There are currently no physical indicators or lab tests that can diagnose the condition.

Researchers are turning to fungi to treat covid!

In an upcoming clinical trial, agarikon and turkey tail mushrooms will be given to covid-positive patients with mild symptoms. Researchers hope that the mushrooms’ antiviral and immune-boosting properties will prevent symptoms from worsening.

In a separate trial, the same blend of mushrooms will be given to subjects while getting vaccinated to see if it can boost antibody levels.

Industry Quick Hits

Nov 22 – Emyria Ltd (EMD) receives $5 million from one of Australia’s largest private investment groups Read more…

Nov 23 – Cybin (CYBN) Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities Read more…

Nov 23 – COMPASS Pathways (CMPS) granted fifth US patent for crystalline psilocybin Read more…

Nov 24 – Seelos Therapeutics (SEEL) Acquires Exclusive License of iX Biopharma’s Proprietary Wafer-Based Ketamine Delivery Platform Read more…

Nov 24 – NeonMind (NEON) Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001  Read more…

Nov 26 – Numinus (NUMI) Receives Conditional Approval to Graduate to the Toronto Stock Exchange Read more…

Video of the Week

Inside the LSD Museum That the DEA Somehow Hasn’t Nuked

Playlist of the Week

60s - 70s stoner rock
Posted on

NeonMind Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001

NeonMind Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001

  • FDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss 
  • Company plans to file an IND application for a Phase 1/2 clinical study anticipated to start in H1’2022

Vancouver, B.C. – November 23, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today it successfully completed a pre-Investigational New Drug (IND) consultation with the U.S. Food and Drug Administration (FDA), regarding proposed clinical trials for NeonMind’s lead obesity drug candidate, NEO-001. The Company expects to initiate a Phase 1/2 clinical study in the first half of 2022.

“We are extremely pleased with the FDA’s feedback and the outcome of the pre-IND consultation, which validated the scientific hypothesis and clinical approach developed by the NeonMind team. The FDA provided helpful feedback and constructive recommendations for the next steps in our development plan. We appreciate the FDA’s guidance and are on track to bring the first and only psychedelic-based treatment for obesity into clinical trials,” said Robert Tessarolo, President & CEO of NeonMind. “In parallel with an IND submission, we plan to engage with a Contract Research Organization and qualify clinical sites to move expeditiously into a Phase 1/2 Proof-of-Concept study.”

The pre-IND consultation offered feedback for NeonMind to execute on measurable clinical development milestones for its NEO-001 clinical program. The FDA acknowledged the study rationale and potential therapeutic opportunity of NEO-001 for the treatment of obesity, and the justification to advance into human clinical trials. NeonMind will incorporate the FDA’s recommendations and does not expect any impact on the timing of the proposed NEO-001 clinical program. NeonMind’s proprietary therapy will be the first psychedelic program in humans to target a large population of patients struggling with sustainable weight management.

NEO-001, the Company’ lead drug candidate targeting obesity, is a high-dose psilocybin treatment coupled with behavioral therapy and lifestyle intervention, which aims to improve the efficacy of chronic weight management in adults. The Company has identified a regulatory strategy, including a target indication and product profile, which it believes will best position NeonMind as it advances its first lead candidate through development.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind, and its strategic medical services partner, SRx Health Solutions,  expect to launch NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to  www.NeonMindBiosciences.com.


Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Allied Corp Signs Yearly Supply Contract With Veterans for Healing Using the Allied Inside™ Business Model With Colombian Produced Cannabis Flower

KELOWNA, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) is pleased to announce the signing of a supply contract (the “contract”) for the 2022 calendar year and beyond. Allied will be only exporting cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States only allows for THC levels to be less than 0.3%).

On November 18th 2021, a contract was signed between Allied and a globally focused veterans innovative healing organization called Veterans For Healing(“VFH”) for a volume of 4000 kilograms per month of Colombian produced 20%+ high-CBD percentage flower. 2000 kilograms monthly is destined for the United States and 2000 kilograms monthly is destined for the United Kingdom. The intent is that this flower will be processed into high percentage CBD content cigarette packages for sale into the United States and United Kingdom markets. These cigarette packages will be branded with the VFH brand with the Allied Inside™ mark on the package. The Allied Inside™ mark signifies that there is Allied Corp produced flower contained.

About Allied Inside™ Model: Click for more here

The Allied Inside™ value proposition enables national brands and companies to brand, market and sell their retail products into their market with the Allied Inside™ product contained. The Allied product is produced in Colombia and provided as a wholesale product to many international partners to then distribute and sell. The Allied Inside™ model offers qualified clients the ability to import large volumes of Colombian produced flower with a small up front percentage of payment and the remainder due under terms of future payment (ie 60-90days). This enables off-take partners to sell into their market and essentially pay for the remainder of the payment out of their sales revenue.

About Veterans for Healing:

Veterans For Healing (“VFH”) is a globally reputed company that has been gained, through tangible action within several countries around the globe, a strong Veterans following as an advocate for veteran help, health and healing.

VFH has partners in many countries around the globe that serve veterans in every aspect of health and wellness. Within their global network, VFH is committed to ensuring premium quality products, consistent supply and proven genetics, for their client’s medical cannabis needs. VFH helps by guiding Veterans through Veterans Affairs organizations and helping with medical authorizations as needed. VFH also has ready access to psychologists, psychiatrists, physicians, natural health companies and coordinators in many countries.

VFH can offer education on medical cannabis for optimizing results, access to online yoga, peer support and other healing practices and connection into a peer cohort that offers healing events and gatherings for Veterans and their families. For more on VFH please click here: CLICK FOR MORE ON VFH.

“We are excited to bring the Allied Inside™ business model to market. In my opinion, Veterans for Healing is the perfect partner. As Colombia continues to move towards the ability to export cannabis flower to countries where it is legal to do so, these contracts point to the demand that the global cannabis market is asking for. We believe that these supply contracts are just the start of Allied’s production volumes. We harvest on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week. We also continue to build relationships with buyers in many different countries around the globe and, through this, we believe that we are ready to supply the market demand in many international markets where it is legal to do so.” said Mr. Calum Hughes, CEO and Chairman of Allied Corp.

About Allied Corp. – https://allied.health/

Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD.

Investor Relations:
ir@allied.health
1-877-255-4337

Forward-Looking Statements:
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF™ branded products, and the use of proceeds from the offering of convertible notes.

There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company’s continuous disclosure including its Management’s Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company’s profile at www.sec.gov.

Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

Posted on

LOVE Pharma Signs Letter Of Intent To Acquire 100% Interest In Microdoz Therapy Inc. To Expedite Pilot Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder With World Leading University

LOVE Pharma Signs Letter Of Intent To Acquire 100% Interest In Microdoz Therapy Inc. To Expedite Pilot Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder With World Leading University

VANCOUVER, BC, CANADA (November 23, 2021) – LOVE Pharma Inc. (“LOVE” and or the “Company”)(CSE: LUV) (FSE: G1Q0), is pleased to announce that it has executed a Letter of Intent (”LOI”) to acquire 100% of MicroDoz Therapy Inc. (“MicroDoz”), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Upon the closing of the definitive agreement, the Company expects to release the details of the program and university partner.

This new partnership and development program will add to the Company’s comprehensive portfolio of intellectual property and further validate the Company’s effort to be a frontrunner in the psychedelics and therapeutics space.

Terms of the Deal:

  • $1,000,000 CAD payable in common shares of the Company subject to certain escrow provisions at a deemed price of $0.05 per share
  • 50% payable at closing of the proposed transaction which is anticipated to close in 30 days
  • Remaining 50% will be paid in four equal tranches over a 2-year period subject to the successful completion of certain milestones to be established in the definitive agreement

“LOVE’s existing portfolio is at the leading edge of innovation and our new product development will continue to build upon that foundation, aiming to establish new customer applications as we seek to define the psychedelics and therapeutics space,”  said Mr. Zach Stadnyk, LOVE President and CEO. “Science and efficacy are paramount to our strategy, as a result we seized the opportunity to acquire MicroDoz to expedite what will be a landmark study with a world leading university to establish our Biosynthetic Psilocybin Infused Oral Strip as a product with the highest standard of efficacy, establishing the highest level of consumer confidence.“

In addition, pursuant to the company’s stock option plan, the Company has issued 19,250,000 incentive stock options to certain officers, directors, employees, and consultants of the issuer exercisable at a price of $0.05 per share for a period of five (5) years, vesting immediately.


About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, LOVE Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life.  LOVE Pharma Inc. holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Disclaimer

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities legislation (together, “forward-looking statements”. Forward-looking statements can be identified by the expressions “seeks”, “expects”, “believes”, “estimates”, “will”, “target” and similar expressions. The forward-looking statements are not historical facts, but reflect the current expectations of the Company regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking events and circumstances discussed in this release include, but are not limited to, the acquisition of MicroDoz and the timing of the acquisition, the possibility of success associated with the study, the ability of the Company to fulfill all conditions to closing, and the outcome and anticipated benefits of the acquisition. All forward-looking statements in this press release are qualified by these cautionary statements. The Company believes that the expectations reflected in forward-looking statements are based upon reasonable assumptions; however, the Company can give no assurance that the actual results or developments will be realized by certain specified dates or at all. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, a forward-looking statement speaks only as of the date on which such statement is made. The Company undertakes no obligation to publicly update any such statement or to reflect new information or the occurrence of future events or circumstances except as required by securities laws. These forward-looking statements are made as of the date of this press release. These forward-looking statements may be affected by risks and uncertainties in the business of Appreciated and Trinity and general market conditions, including COVID-19.

Posted on

HAVN Life Successfully Exports Psilocybin From Its Jamaica Facility Into Canada

HAVN Life Successfully Exports Psilocybin From Its Jamaica Facility Into Canada

The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica.

The importation of the naturally derived psilocybin into Canada was completed after the Company entered into a supply agreement with Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Based out of Victoria, British Columbia, Nectar Health Sciences Laboratory Division Inc. has a Controlled Substance Dealer’s License for the relevant psychedelic compounds issued by Health Canada. Under that license, Nectar was granted an import permit, pursuant to the provisions of the Controlled Drugs and Substances Act and the Food and Drugs Regulations.

The agreement with Nectar Health Sciences Laboratory Division Inc. paves the way for HAVN Life’s successful exportation of naturally derived psilocybin from Jamaica. Additionally, it validates the Company’s supply chain business model of providing psilocybin for clinical use and research, adding to previously announced supply partnerships this year with Mycrodose Therapeutics, Mycotopia Therapies, Cube Psytech, Allied Health, ATMA Journey Centers, Revive Therapeutics and HealthTech Connex.

“This partnership is a huge win for us as we look to secure additional supply agreements with Canadian companies, now that the integrity of our supply chain from Jamaica has been demonstrated,” says HAVN Life CEO, Tim Moore. “As the research and drug development work on psilocybin moves forward, HAVN Life continues to position itself as a supply chain leader, able to meet the demand for naturally derived psilocybin,” he adds.

“We are pleased to be one of HAVN Life Sciences preferred supply partners,” says Kevin Coft, CEO of Psilobrain Therapeutics Inc. “Our Nectar Health Sciences Laboratory Division has been at the forefront of synthetic psychedelic research, and our supply agreement with HAVN Life Sciences compliments and initiates our next stage of comprehensive testing, analytics, extraction, and product development from psychedelic mushrooms cultivated and processed under stringent quality control protocols,” he adds.

The agreement and supply of psilocybin to Nectar Health Sciences Laboratory Division Inc. will be in compliance with all applicable Health Canada regulations.

###

 On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Psilobrain Therapeutics Inc.

Psilobrain Therapeutics Inc. is a Canadian biotech company that draws on the latest advances in psychedelic medicine to produce scientifically designed products to facilitate evidence-based healing and wellness. Backed by our 3 Health Canada licenses, we ensure the highest quality of standard by integrating and controlling all aspects of the supply chain from sourcing our naturally derived psilocybin for research-developed formulations through our licensed R&D laboratory.

Psilobrain is committed to our Drug Development Program, with 3 provisional patents and numerous preclinical studies in various stages of research and data collection. and is an active contributor in the pharmaceutical, nutraceutical and psychedelic wellness industries. In addition to drug development, Psilobrain has partnered with Psychedelic Wellness Clinics to support emerging psychedelic therapies by collaborating with Clinical Counsellors on psychedelic prescription research, product development & data collection.

Our Management and Advisory team are industry veterans in the pharmaceutical & consumer goods industries. Members of our team have held C-suite and other senior positions within companies such as Med BioGene, Aspreva Pharmaceuticals, Teva Pharmaceutical Industries, Mount Sinai, Social Creatures, Green Sky Labs, Jimmy Pattison Group, and the British Columbia Association of Clinical Counsellors. Psilobrain Therapeutics is committed to our research-based approach of developing new modalities for healing and is well-positioned to bring that wellness to the community.

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

Contact:

Investor Relations: ir@havnlife.com  604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the supplying agreement with Nectar Health Sciences Laboratory Division Inc. (the “Supply Agreement”), the exportation and importation of psilocybin-containing mushrooms, compliance with Health Canada regulations (the “Health Canada Compliance”), the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipated benefits of the Supply Agreement will not be realized as contemplated, or at all, risks that the continued exportation and importation of psilocybin-containing mushrooms may not be completed as contemplated, or at all, risks that the Company may not be able to obtain or maintain Health Canada Compliance as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

Kids try ketamine in the metaverse: issue 24

Here’s what’s in store for you in today’s issue:

🍄 Psychedelic therapy enters the Metaverse?!

🍄 Kids try ketamine

🍄 How psychedelics help you manage stress

🍄 Microdosing for a better sleep

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Functional Mushrooms for Health & Nutrition with FreshCap CEO Tony Shields

In the episode of the Daily Mushroom Podcast, we have Tony Shields, CEO of FreshCap. Tony’s knowledge on mushrooms is deep and expansive and stems from a childhood fascination with these magnificent fungi. If you want to learn more about the benefits of functional mushrooms, this podcast is for you.

Therapeutic banner

How psychedelics help you manage stress

Psychedelic drug users had less psychological distress and more social support during pandemic lockdowns, according to a recent Tilburg University survey. 

Users were more likely to spend time outdoors, maintain healthy diets, meditate, play music, and do yoga. Non-users spent more time watching TV and following COVID news.

Ditch your opioid addiction

A new study found that people who used psychedelics within the past six months were 55% less likely to use opioids daily. 

Can microdosing before bed help you sleep better? 

MindMed (MNMD) launched a study to investigate the effects of microdosing LSD in the morning versus the evening.

Researchers will use digital devices and software to track:

  • Various sleep measures
  • Neuroplasticity
  • Mood
  • Cognitive function
  • Regulation of emotions
  • Quality of life &
  • Immune function

Too much screen time, shopping, or sex? 

Clearmind Medicine’s (CMND) proprietary compound could treat alcohol addiction, but that’s not all. It is now being evaluated to treat other addictive behaviours such as compulsive consumption of food, television, technology, shopping, gambling, and even sex.

Reducing alcohol cravings

A study discovered that psilocybin can reduce the odds of alcohol relapse! 

How does it work? Alcohol reduces a protein in the brain called mGluR2. In a rat model, researchers found that the more protein lost, the more alcohol the rats craved, creating an addictive cycle.

Psilocybin was able to restore protein levels, thus decreasing relapses.

inspirational banner

Psychedelic therapy enters the Metaverse?!

Tennessee-based ketamine company Revitalist (CALM) announced that it’s developing a mental health clinic in the Metaverse 🤯

Patients will be able to attend VR therapy sessions, pay with cryptocurrency, and earn NFTs as part of a rewards program.

Should kids try ketamine?

Most parents think they should! 

A survey shows that parents, especially those who have experienced mental illness, are very open to ketamine therapy for children. The average acceptance score was 7/10 and over 60% said they would allow their child to try ketamine therapy to treat depression. 

business banner

Allied Corp. (ALID) sourced the active ingredients to produce Psilonex™, its formulation of psilocybin, functional mushrooms, and vitamins. It will be used in conjunction with a daily dose of CBD in an upcoming clinical trial on depression, anxiety, and PTSD.

Way2Grow Biopharma, a private BC company, received a license from Health Canada to create a psychedelic production campus. The company can produce up to $30 worth of compounds to sell to pharmacies and clinics.

Delic (DELC) launched a free, virtual education program to teach the families of ketamine therapy patients how they can best support their loved ones through the healing journey.

These companies announced their quarterly highlights:

legal banner

Suing for access to MDMA

A psychiatrist is suing the Australian state of Victoria for denying a patient access to MDMA-assisted therapy. The case has been adjourned until early next year, as the government may decide to reschedule MDMA from a Schedule 9 to a Schedule 8 substance.

Tackling one of the biggest litter problems in the world!

Researchers in Australia are training oyster mushrooms to digest cigarette butts, including their microplastics. The goal is to turn some of the 4.5 trillion cigarette butts that are littered annually into a reusable material!

Need a brain-boost?

Try FreshCap’s Mushroom Coffee to have the most productive day ever!

Made with organic Lion’s Mane mushrooms to support cognition, immune-boosting Chaga, and stress-relieving Ashwagandha, it’s everything you love about coffee – made even better.

Use promo code DAILY for 10% off your order at FreshCaps.com! 

You’re welcome in advance 😉

Industry Quick Hits

Nov 15 – Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets Read more…

Nov 16 – Michael J. Fox Foundation Donates $2M to Fund Ketamine Trial to Treat Depression in Patients with Parkinson’s Disease Read more…

Nov 16 – Ketamine One (MEDI) Subsidiary IRP Health Opens Two New Veteran-Focused Clinics in Comox Valley and Ottawa Read more…

Nov 17 – Pasithea Therapeutics (KTTA) Expands At-Home Ketamine Therapy to New York City, Los Angeles, San Diego, and San Francisco Read more…

Nov 19 – Numinus to Begin Trading on the OTC Under Symbol “NUMIF” Read more…

Nov 19 – PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications Read more…

Video of the Week

Jada and Jaden Smith Discuss Psychedelics

Playlist of the Week

60s - 70s stoner rock
Posted on

NeonMind To Participate In Panel Discussion At Lift & Co. Expo’s Psychedelics Business Summit On November 19, 2021

NeonMind To Participate In Panel Discussion At Lift & Co. Expo’s Psychedelics Business Summit On November 19, 2021

Vancouver, B.C. – November 17, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, is pleased to announce that President and CEO, Rob Tessarolo, is scheduled to participate in a panel discussion at Lift & Co. Expo’s new Psychedelics Business Summit, on November 19, 2021, in Toronto. The panel entitled, “Business Leaders: Committing to Business Strategies and Approaches that Will Benefit Patients – and Investors,” will include Canada’s leading psychedelics entrepreneurs in medical research, clinical therapy, product innovation and business investment.

 

Lift Psychedelics Business Summit

Place:  Metro Toronto Convention Center, North Building

Date:  Friday, November 19, 2021

Time:  2:45 pm – 3:45 pm EST

Registration:  liftexpo.ca

 

Building on the success of psychedelics content launched at the Cannabis Business Conference Vancouver in 2020, The Lift Psychedelics Business Summit will take a deep dive into psychedelics research and the psychedelics industry. It is structured to offer attendees the most up-to-date business intelligence, specifically on the four pillars of today’s psychedelic renaissance: medical research, legalization and investment for a professional and business-focused audience.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to  www.NeonMindBiosciences.com.

 

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.